Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Black-Box Warning For Harvoni, Sovaldi, Viekira Pak: Hepatitis B Risk

October 7, 2016 By Law Offices of Thomas J. Lamb, P.A.

Direct-acting antivirals (DAAs) are a class of prescription medicines that are FDA-approved to treat adults with hepatitis C virus (HCV) infection. These medicines are available as single-ingredient products and also in combination with other HCV medicines.

Here is a list of direct-acting antivirals currently available in the US:

Daklinza (daclatasvir) — Bristol-Myers Squibb
Epclusa (sofosbuvir and velpatasvir) — Gilead Sciences
Harvoni (ledipasvir and sofosbuvir) — Gilead Sciences
Olysio (simeprevir) — Janssen
Sovaldi (sofosbuvir) — Gilead Sciences
Technivie (ombitasvir and paritaprevir and ritonavir) — Abbvie
Viekira Pak (dasabuvir and ombitasvir and paritaprevir and ritonavir) — Abbvie
Viekira Pak XR (dasabuvir and ombitasvir and paritaprevir and ritonavir) — Abbvie
Zepatier (elbasvir and grazoprevir) — Merck Sharp Dohme

In October 2016 the FDA indicated their concern about these relatively new drugs — such as Harvoni, Sovaldi, and Viekira Pak — which are increasingly popular for treating chronic hepatitis C by issuing a Drug Safety Communication which started with this statement:

The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks.

As a result, FDA is requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation to be added to the drug labels of these DAAs directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment. This warning will also be included in the patient information leaflet or Medication Guides for these medicines.

The FDA has advised patients using any of these DAA medicines for treat chronic hepatitis C virus (HCV) infection to contact their health care professional immediately if they develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be signs of serious liver problems.

Of course, we will continue to monitor the safety profiles of Harvoni, Sovaldi, and Viekira Pak, as well as the several other direct-acting antiviral (DAA) medicines, and report further significant developments.

[Read this article in full at original source]

Harvoni / Sovaldi / Viekira Pak

Free Case Evaluation

Strictly Confidential, No Obligation


Filed Under: Unsafe Drugs Tagged With: Daklinza, Epclusa, Harvoni, Hepatitis, Olysio, Sovaldi, Technivie, Viekira Pak, Zepatier

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.